Published in J Urol on October 01, 1984
The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol (1995) 1.09
The use of the BTA Test in the detection of persistent or recurrent transitional-cell cancer of the bladder. World J Urol (1997) 0.78
A Comparison Between ThinPrep Monolayer and Cytospin Cytology for the Detection of Bladder Cancer. Korean J Urol (2014) 0.77
The role of collecting bladder wash fluid before biopsy procedure to help the cytological diagnosis of residual tumor. J Cytol (2015) 0.75
Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med (1981) 5.44
Genetics of natural resistance to herpesvirus infections in mice. Nature (1975) 3.18
The family Herpesviridae: an update. The Herpesvirus Study Group of the International Committee on Taxonomy of Viruses. Arch Virol (1992) 3.09
The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol (1993) 2.95
Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides. J Med Chem (1979) 2.80
What young men know about testicular cancer. Prev Med (1983) 2.08
2'-fluoro-5-iodo-aracytosine, a potent and selective anti-herpesvirus agent. Antimicrob Agents Chemother (1980) 1.96
Natural killing of herpes simplex virus type 1-infected target cells: normal human responses and influence of antiviral antibody. Infect Immun (1979) 1.94
Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol (2000) 1.92
Prognostic implications of a positive apical margin in radical prostatectomy specimens. J Urol (1997) 1.83
Association of renal allograft rejection with virus infections. Am J Med (1974) 1.83
Characterization of a new primary human pancreatic tumor line. Cancer Invest (1986) 1.67
The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J Urol (1997) 1.62
Shigella sonnei bacteremia. Unusual antibody response from immunosuppressive therapy following renal transplantation. Urology (1974) 1.53
Cell-mediated immune responses in recurrent herpesvirus infections. I. Lymphocyte proliferation assay. J Immunol (1977) 1.51
Secondary tumors of the prostate. J Urol (1985) 1.48
Toward an ecosocial view of health. Int J Health Serv (1999) 1.47
Accuracy of magnetic resonance imaging of inguinofemoral lymph nodes in vulval cancer. Int J Gynecol Cancer (2006) 1.47
Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol (1996) 1.46
Isolation of a virus from the lungs of Montana sheep affected with progressive pneumonia. Virology (1968) 1.46
Intralesional treatment of established murine primary renal tumor with interleukin-4: localized effect on primary tumor with no impact on metastases. J Urol (1995) 1.44
A comparison of the W-stapled ileal reservoir with hand-sewn reservoirs for orthotopic bladder replacement. Urology (1996) 1.40
[Convulsive episode secondary to bupropion in a patient not included in a risk group]. Aten Primaria (2003) 1.40
Histology and prevalence of ovarian tumours in postmenopausal women: is follow-up required in all cases? J Obstet Gynaecol (2012) 1.38
Heterogeneity of human NK cells: comparison of effectors that lyse HSV-1-infected fibroblasts and K562 erythroleukemia targets. J Immunol (1983) 1.37
Cytomegalovirus: Clinical virological correlations in renal transplant recipients. Ann Surg (1974) 1.34
High flow malignant priapism with isolated metastasis to the corpora cavernosa. Urology (1998) 1.31
1,000 consecutive ultrasounds for blunt abdominal trauma. J Trauma (1996) 1.31
Facilitation or attenuation of mixed leukocyte culture responsiveness by adherent cells. Nature (1976) 1.31
Haematogenous dissemination of cells from human renal adenocarcinomas. Br J Cancer (1988) 1.30
Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology (1998) 1.26
Conservative surgery for renal cell carcinoma: a single-center experience with 100 patients. J Urol (1989) 1.26
High-level transient expression of influenza virus proteins from a series of SV40 late and early replacement vectors. Gene (1988) 1.24
Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res (1994) 1.24
Role of virus infections in immunosuppressed renal transplant patients. Transplant Proc (1973) 1.23
Opportunistic infections in acquired immune deficiency syndrome result from synergistic defects of both the natural and adaptive components of cellular immunity. J Clin Invest (1986) 1.23
Fracture of the outlet strut of a Björk-Shiley mitral prosthesis: emergency operation with survival. J Thorac Cardiovasc Surg (1984) 1.23
Identification of a nucleocapsid protein as a specific serological marker of human herpesvirus 6 infection. J Clin Microbiol (1990) 1.23
Growth properties of human herpesvirus-6 strain Z29. J Virol Methods (1989) 1.23
Renal cell carcinoma with inferior vena cava tumor thrombi. Surg Gynecol Obstet (1991) 1.22
Role of interferon in natural kill of HSV-1-infected fibroblasts. J Immunol (1982) 1.22
Cytogenetic studies of tumor tissue from patients with nonfamilial renal cell carcinoma. Cancer Res (1986) 1.22
Diet in the epidemiology of carcinoma of the prostate gland. J Natl Cancer Inst (1983) 1.22
Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer (1989) 1.21
Correlation between low natural killing of fibroblasts infected with herpes simplex virus type 1 and susceptibility to herpesvirus infections. J Infect Dis (1983) 1.19
NCCN Practice Guidelines for Prostate Cancer. Oncology (Williston Park) (2000) 1.19
Recurrent Salmonella typhimurium bacteremia associated with the acquired immunodeficiency syndrome. Ann Intern Med (1985) 1.17
Resistance to herpes simplex virus - type 1 (HSV-1). Curr Top Microbiol Immunol (1981) 1.17
Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res (2001) 1.17
Severe acquired immune deficiency syndrome in male homosexuals: diminished capacity to make interferon-alpha in vitro associated with severe opportunistic infections. J Infect Dis (1983) 1.16
Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol (1998) 1.16
Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology. Eur Radiol (2010) 1.15
Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology (1995) 1.14
Efficacy and selectivity of some nucleoside analogs as anti-human cytomegalovirus agents. Antimicrob Agents Chemother (1983) 1.14
Experience with cardiopulmonary bypass and deep hypothermic circulatory arrest in the management of retroperitoneal tumors with large vena caval thrombi. Ann Surg (1990) 1.13
Management of primary urethral cancer. Urology (1998) 1.13
The noncoding region of HPV-6vc contains two distinct transcriptional enhancing elements. Virology (1986) 1.12
Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol (1987) 1.12
Resistance to HSV-1 in the mouse is governed by two major, independently segregating, non-H-2 loci. Immunogenetics (1980) 1.12
Flow cytometric analysis of DNA aneuploidy in primary and metastatic human solid tumors. Cytometry (1984) 1.11
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol (1997) 1.11
Focal xanthogranulomatous pyelonephritis presenting as a renal tumor with vena caval thrombus. J Urol (1998) 1.10
Vestibular syndrome: a change in internal spatial representation. Neurophysiol Clin (2008) 1.09
Human natural killer cells limit replication of herpes simplex virus type 1 in vitro. J Immunol (1985) 1.09
Human mononuclear cells which produce interferon-alpha during NK(HSV-FS) assays are HLA-DR positive cells distinct from cytolytic natural killer effectors. J Leukoc Biol (1988) 1.07
Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer (1999) 1.07
Marrow transplantation for juvenile osteopetrosis. Am J Med (1981) 1.07
Epidemiology of high grade prostatic intraepithelial neoplasia. Pathol Res Pract (1995) 1.07
Primary prostatic involvement in non-Hodgkin lymphoma. Urology (1988) 1.07
Duplicated inferior vena cava simulating retroperitoneal lymphadenopathy in a patient with embryonal cell carcinoma of the testicle. J Urol (1986) 1.06
Sexual function after radical prostatectomy. Prostate (1986) 1.06
Marrow-dependent cells depleted by 89Sr mediate genetic resistance to herpes simplex virus type 1 infection in mice. Infect Immun (1980) 1.06
Isolation and morphologic characterization of human ovarian carcinoma cell clusters present in effusions. Exp Cell Biol (1987) 1.05
Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder. J Urol (1977) 1.05
High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res (1996) 1.05
Thermodynamic analysis of calcium and magnesium binding to calmodulin. Biochemistry (1998) 1.05
Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype. Cancer Genet Cytogenet (1993) 1.05
Anterior urethral injuries: four years of experience at the Detroit General Hospital. J Urol (1978) 1.04
Metastatic breast carcinoma to the bladder. J Urol (1970) 1.04
Isolation of Aleutian mink disease virus by affinity chromatography. Science (1973) 1.04
Immediate-early gene expression is sufficient for induction of natural killer cell-mediated lysis of herpes simplex virus type 1-infected fibroblasts. J Virol (1991) 1.04
The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol (1982) 1.04
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer (1983) 1.04
Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol (2000) 1.04
Chemotherapy of bladder carcinoma with cyclophosphamide and adriamycin. J Urol (1975) 1.03
Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer (1980) 1.03
Urological injuries associated with pelvic trauma. J Urol (1979) 1.03
Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate (1989) 1.03
Immunological nature of genetic resistance of mice to herpes simplex virus type 1 infection. IARC Sci Publ (1978) 1.03
Replication of herpes simplex virus type 1 in macrophages from resistant and susceptible mice. Infect Immun (1979) 1.02
Oxidative stress and activation of proteasome protease during serum deprivation-induced apoptosis in rat hepatoma cells; inhibition of cell death by melatonin. Apoptosis (2003) 1.01
Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology (1999) 1.01
Should the age specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years? J Urol (2000) 1.01
Studies of the cell lineage of the effector cells that spontaneously lyse HSV-1 infected fibroblasts (NK(HSV-1)). J Immunol (1982) 1.00
The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol (1989) 1.00
Proliferative characteristics of primary and metastatic human solid tumors by DNA flow cytometry. Cytometry (1984) 0.99
Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res (1994) 0.98